Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research

Novavax (NASDAQ:NVAX) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on NVAX. Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. BTIG Research restated a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a report on Tuesday. B. Riley Financial reiterated a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Finally, TD Cowen raised their price objective on shares of Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Novavax Stock Performance

NVAX opened at $7.95 on Thursday. The business’s 50-day simple moving average is $8.72 and its 200-day simple moving average is $8.97. Novavax has a one year low of $6.20 and a one year high of $11.97. The stock has a market capitalization of $1.31 billion, a P/E ratio of -5.23 and a beta of 2.46.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. The firm had revenue of $56.70 million during the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%.The business’s revenue was down 76.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. On average, equities research analysts forecast that Novavax will post -0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Novavax

A number of large investors have recently made changes to their positions in NVAX. Quarry LP acquired a new stake in shares of Novavax in the third quarter valued at about $33,000. Duncker Streett & Co. Inc. grew its position in Novavax by 917.3% during the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 3,825 shares during the period. KBC Group NV grew its position in Novavax by 34.9% during the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,229 shares during the period. Flagship Harbor Advisors LLC purchased a new position in Novavax in the fourth quarter valued at about $33,000. Finally, Danske Bank A S purchased a new position in Novavax in the third quarter valued at about $64,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a second-quarter adjusted loss of $0.32 per share, better than the expected $0.38 loss, while revenue of $56.7 million exceeded estimates of approximately $52.5 million. NVAX Q2 Earnings & Sales Beat Estimates, 2026 Sales Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 adjusted revenue framework to $235 million-$275 million from $230 million-$270 million and reduced combined GAAP research and development and selling, general and administrative expense guidance by $10 million at the midpoint. Novavax Raises 2026 Outlook After Q2 Beat
• Positive Sentiment: Novavax said completion of its manufacturing technology transfer to Sanofi is expected in mid-2027, potentially triggering a $75 million milestone payment. Sanofi also plans to advance discussions with regulators regarding timing for its Phase 3 COVID-19 and influenza combination-vaccine trial. Novavax Lifts Annual Revenue Forecast
• Neutral Sentiment: Novavax ended June with approximately $724 million in cash, cash equivalents, marketable securities and restricted cash. It also highlighted partner-led Matrix-M projects and plans to move its C. difficile vaccine program into clinical development as early as 2027. Novavax Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Revenue fell approximately 76% from the prior-year quarter to $56.7 million, product sales were only $19 million, and Novavax posted a $53 million net loss versus $107 million of net income a year earlier. The results underscore the company’s dependence on licensing revenue and milestone payments as vaccine demand wanes. Novavax Q2 Revenue Falls 76 Percent

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.